Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.75 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.75 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.75 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.75 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.75 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.59 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8658147 | 0.88 | F10 (0.71) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL5595867 | 0.88 | HDAC1 (0.67) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL8401704 | 0.88 | HDAC1 (0.89) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL23500526 | 0.86 | HDAC1 (0.64) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL5226034 | 0.86 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL8242923 | 0.83 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL4921514 | 0.83 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| Dinaline SCHEMBL29354254 | 0.83 | HDAC1 (0.79) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL1060598 | 0.83 | HDAC1 (0.79) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| Dinaline SCHEMBL93636 | 0.83 | HDAC1 (0.79) | HDAC1HDAC3HDAC2HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021115188-A1 | HISTONE DEACETYLASE, AND PROTEASOME DUAL-TARGET INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 山东大学 | 2021-06-17 | — | — | WO | disclosed |
| CN-110950897-B | Histone deacetylase, protease double-target inhibitor, preparation method and application thereof | 山东大学 | 2021-05-28 | — | — | CN | disclosed |
| CN-110950897-A | Histone deacetylase, protease double-target inhibitor, preparation method and application thereof | 山东大学 | 2020-04-03 | — | — | CN | disclosed |
| US-8026239-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-07 | — | — | US | disclosed |
| US-7687525-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-30 | — | — | US | disclosed |
| US-RE40703-E1 | Cell differentiation inducer, benzamide compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-04-28 | — | — | US | disclosed |
| US-20080188489-A1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
| US-7317028-B2 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| US-RE39754-E1 | Benzamide derivatives and pharmaceutical compositions containing same | SCHERING AG (DE) | 2007-07-31 | — | — | US | disclosed |
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6794392-B1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | SCHERING AKTIENGESELLSCHAFT | 2004-07-29 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1437346-A1 | Benzamide derivatives useful as cell differentiation inducers | Schering AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0847992-B1 | Benzamide derivatives, useful as cell differentiation inducers | SCHERING AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
| US-6174905-B1 | AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA | MITSUI CHEMICALS, INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0847992-A1 | Benzamide derivatives, useful as cell differentiation inducers | Mitsui Chemicals, Inc. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188489-A1 | Cell differentiation inducer | MCL1, MYADM, MYD88 | HDAC1 150/4885HDAC3 618/4885HDAC2 170/4885 |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | MCL1, MYADM, PDCD1 | HDAC1 81/4885HDAC3 807/4885HDAC2 204/4885 |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | MCL1, MYADM, MYD88 | HDAC1 163/4885HDAC3 680/4885HDAC2 183/4885 |
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | HDAC1 976/4885HDAC3 1616/4885HDAC2 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.